Pulnovo Accelerates Global Strategy With Financing Round

Shanghai – November 22, 2022 – A Cooley team advised Pulnovo Medical, a medical device company specializing in the treatment of cardiopulmonary disease, on its recent financing round. Partner Yiming Liu led the Cooley team advising Pulnovo.

The financing was led by YuanBio Venture Capital and other investors, including OrbiMed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures, Gaorong Capital, Huihe Capital and GC&H Investments. The funding – an undisclosed amount totaling tens of millions of dollars – will enable Pulnovo to accelerate its pulmonary artery denervation Food and Drug Administration global trial, expand its research and development capability in cardiopulmonary disease treatment, and execute marketing and commercialization strategy.

Established in 2013, Pulnovo is recognized as a pioneer in developing devices to treat cardiopulmonary diseases and is committed to researching and developing therapeutic solutions, alongside physicians, to benefit patients around the world.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has 1,500 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of 3,300.